$IMNM
Immunome Inc.

2021 Q4 Form 10-Q Financial Statement

#000155837021015969 Filed on November 15, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.459M $3.210M $2.240M
YoY Change 54.42% 174.36% 46.89%
% of Gross Profit
Research & Development $4.385M $4.513M $1.840M
YoY Change 138.32% 174.51% -79.15%
% of Gross Profit
Depreciation & Amortization $118.0K $286.0K $260.0K
YoY Change -54.62% 58.89% -18.75%
% of Gross Profit
Operating Expenses $7.844M $7.723M $4.070M
YoY Change 92.73% 174.06% -60.67%
Operating Profit -$7.723M
YoY Change 174.06%
Interest Expense -$5.000K -$3.000K $0.00
YoY Change -99.95% -100.0%
% of Operating Profit
Other Income/Expense, Net -$3.000K $6.000K
YoY Change -99.89%
Pretax Income -$7.852M -$7.720M -$4.070M
YoY Change 92.92% -7.88% -61.03%
Income Tax
% Of Pretax Income
Net Earnings -$7.852M -$7.720M -$4.070M
YoY Change 92.92% -7.84% -61.03%
Net Earnings / Revenue
Basic Earnings Per Share -$0.65
Diluted Earnings Per Share -$648.5K -$646.9K -$381.8K
COMMON SHARES
Basic Shares Outstanding 12.10M 11.81M 10.54M
Diluted Shares Outstanding 11.93M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $49.23M $56.24M $39.77M
YoY Change 23.78% 734.47%
Cash & Equivalents $49.23M $56.24M $39.77M
Short-Term Investments
Other Short-Term Assets $7.409M $4.947M $3.130M
YoY Change 136.71% 568.51%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $56.64M $61.19M $42.89M
YoY Change 32.04% 717.72% 1273.93%
LONG-TERM ASSETS
Property, Plant & Equipment $855.0K $961.0K $1.531M
YoY Change -44.15% -44.8% -9.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $432.0K $407.0K $100.0K
YoY Change 332.0% -84.69% -27.54%
Total Long-Term Assets $1.287M $1.368M $1.631M
YoY Change -21.09% -69.6% -15.84%
TOTAL ASSETS
Total Short-Term Assets $56.64M $61.19M $42.89M
Total Long-Term Assets $1.287M $1.368M $1.631M
Total Assets $57.93M $62.56M $44.53M
YoY Change 30.1% 422.06% 779.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.077M $3.277M $1.187M
YoY Change 159.22% 24.74% 116.61%
Accrued Expenses $6.651M $4.472M $1.372M
YoY Change 384.77% 91.93% 106.01%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $16.00K $366.0K
YoY Change -100.0% -94.75%
Total Short-Term Liabilities $9.728M $7.765M $3.038M
YoY Change 220.21% 43.64% 82.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $134.0K
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $12.00K $0.00 $10.00K
YoY Change 20.0% -100.0%
Total Long-Term Liabilities $12.00K $0.00 $134.0K
YoY Change -91.04% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.728M $7.765M $3.038M
Total Long-Term Liabilities $12.00K $0.00 $134.0K
Total Liabilities $9.740M $7.765M $3.180M
YoY Change 206.29% -38.85% 77.06%
SHAREHOLDERS EQUITY
Retained Earnings -$79.11M -$71.30M -$54.40M
YoY Change 45.41% 41.75% 48.63%
Common Stock $1.000K $1.000K $1.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $48.19M $54.79M $41.35M
YoY Change
Total Liabilities & Shareholders Equity $57.93M $62.56M $44.53M
YoY Change 30.1% 422.06% 779.94%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q4
OPERATING ACTIVITIES
Net Income -$7.852M -$7.720M -$4.070M
YoY Change 92.92% -7.84% -61.03%
Depreciation, Depletion And Amortization $118.0K $286.0K $260.0K
YoY Change -54.62% 58.89% -18.75%
Cash From Operating Activities -$6.805M -$4.145M -$6.060M
YoY Change 12.29% 63.83% 22.67%
INVESTING ACTIVITIES
Capital Expenditures -$14.00K -$26.00K -$50.00K
YoY Change -72.0% -78.33% -73.68%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$14.00K -$26.00K -$50.00K
YoY Change -72.0% -78.33% -73.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $41.70M $41.70M
YoY Change 0.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -195.0K 585.0K 39.13M
YoY Change -100.5% -246.25% 785.29%
NET CHANGE
Cash From Operating Activities -6.805M -4.145M -6.060M
Cash From Investing Activities -14.00K -26.00K -50.00K
Cash From Financing Activities -195.0K 585.0K 39.13M
Net Change In Cash -7.014M -3.586M 33.02M
YoY Change -121.24% 17.57% -4750.7%
FREE CASH FLOW
Cash From Operating Activities -$6.805M -$4.145M -$6.060M
Capital Expenditures -$14.00K -$26.00K -$50.00K
Free Cash Flow -$6.791M -$4.119M -$6.010M
YoY Change 13.0% 70.91% 26.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001472012
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1667
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12093333
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10634245
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39580
dei Entity Registrant Name
EntityRegistrantName
Immunome, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0694340
dei Entity Address Address Line1
EntityAddressAddressLine1
665 Stockton Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
Exton
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19341
dei City Area Code
CityAreaCode
610
dei Local Phone Number
LocalPhoneNumber
321-3700
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
dei Trading Symbol
TradingSymbol
IMNM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-10000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-5000
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12100387
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56243000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39766000
CY2021Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
4947000
CY2020Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
3128000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12093333
CY2021Q3 us-gaap Assets Current
AssetsCurrent
61190000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
42894000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
961000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1531000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2021Q3 us-gaap Deferred Costs
DeferredCosts
307000
CY2021Q3 us-gaap Assets
Assets
62558000
CY2020Q4 us-gaap Assets
Assets
44525000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3277000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1187000
CY2021Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
4472000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1372000
CY2021Q3 imnm Current Portion Of Equipment Loan Payable
CurrentPortionOfEquipmentLoanPayable
16000
CY2020Q4 imnm Current Portion Of Equipment Loan Payable
CurrentPortionOfEquipmentLoanPayable
113000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
366000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7765000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3038000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
134000
CY2020Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
8000
CY2021Q3 us-gaap Liabilities
Liabilities
7765000
CY2020Q4 us-gaap Liabilities
Liabilities
3180000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10634245
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
126045000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
95738000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-71253000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54394000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
54793000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
41345000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
62558000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44525000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4513000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1644000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9725000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5651000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3210000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1174000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7635000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2537000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
7723000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
2818000
us-gaap Operating Expenses
OperatingExpenses
17360000
CY2021Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-3000
us-gaap Operating Expenses
OperatingExpenses
8188000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7723000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2818000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17360000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-27000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-7720000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-8377000
us-gaap Net Income Loss
NetIncomeLoss
-16859000
us-gaap Net Income Loss
NetIncomeLoss
-13764000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65
imnm Stock Issued During Period Value Common Stock And Warrants
StockIssuedDuringPeriodValueCommonStockAndWarrants
26666000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2229000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1338000
imnm Stock Issued During Period Value Stock Options Exercised And Vesting Of Restricted Stock
StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfRestrictedStock
74000
us-gaap Net Income Loss
NetIncomeLoss
-16859000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
54793000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.52
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.49
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-12.44
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11934491
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1114427
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11348856
us-gaap Operating Income Loss
OperatingIncomeLoss
-8188000
CY2020Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5549000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5549000
CY2021Q3 us-gaap Other Income
OtherIncome
6000
us-gaap Other Income
OtherIncome
506000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1106039
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
60617000
CY2021Q3 imnm Stock Issued During Period Value Common Stock And Warrants
StockIssuedDuringPeriodValueCommonStockAndWarrants
262000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1155000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
432000
CY2021Q3 imnm Stock Issued During Period Value Stock Options Exercised And Settlement Of Restricted Stock Units
StockIssuedDuringPeriodValueStockOptionsExercisedAndSettlementOfRestrictedStockUnits
47000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-7720000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
54793000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
41345000
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
559000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-40829000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
117000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
4000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-8377000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-49085000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-35630000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
302000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
7000
us-gaap Net Income Loss
NetIncomeLoss
-13764000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-49085000
us-gaap Net Income Loss
NetIncomeLoss
-16859000
us-gaap Net Income Loss
NetIncomeLoss
-13764000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
637000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
499000
us-gaap Share Based Compensation
ShareBasedCompensation
2229000
us-gaap Share Based Compensation
ShareBasedCompensation
302000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5549000
imnm Deferred Rent
DeferredRent
-8000
imnm Deferred Rent
DeferredRent
-1000
imnm Forgiveness Of Ppp Loan
ForgivenessOfPppLoan
-500000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1819000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56243000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6744000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
151000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2088000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
999000
imnm Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
2811000
imnm Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
495000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11421000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6072000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
65000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
540000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-65000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-540000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
11046000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
27000
imnm Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
27225000
imnm Payments Of Common Stock And Warrants Issuance Costs
PaymentsOfCommonStockAndWarrantsIssuanceCosts
559000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
74000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1338000
imnm Payments Of Stock Issuance Costs Relating To Temporary Equity
PaymentsOfStockIssuanceCostsRelatingToTemporaryEquity
309000
imnm Payment Of Offering Costs
PaymentOfOfferingCosts
18000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
500000
imnm Repayments Of Equipment Loan
RepaymentsOfEquipmentLoan
97000
imnm Repayments Of Equipment Loan
RepaymentsOfEquipmentLoan
165000
imnm Repayments Of Capital Lease Obligations
RepaymentsOfCapitalLeaseObligations
239000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27963000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10813000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
16477000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4201000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39866000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2643000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56343000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6844000
us-gaap Interest Paid Net
InterestPaidNet
27000
imnm Liability Classified Warrants Issued In Connection With Convertible Preferred Stock Fair Value
LiabilityClassifiedWarrantsIssuedInConnectionWithConvertiblePreferredStockFairValue
1522000
imnm Non Cash Transactions Convertible Preferred Stock And Warrants Issuance Costs In Accounts Payable
NonCashTransactionsConvertiblePreferredStockAndWarrantsIssuanceCostsInAccountsPayable
22000
imnm Stock Issuance Costs Included In Accounts Payable And Accrued Expenses And Other Liabilities Current
StockIssuanceCostsIncludedInAccountsPayableAndAccruedExpensesAndOtherLiabilitiesCurrent
2221000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2000
imnm Offering Cost In Accounts Payable
OfferingCostInAccountsPayable
289000
us-gaap Net Income Loss
NetIncomeLoss
-16900000
us-gaap Net Income Loss
NetIncomeLoss
-13800000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-71300000
CY2020Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
41700000
CY2020Q4 imnm Payments Of Underwriting Discounts And Commissions
PaymentsOfUnderwritingDiscountsAndCommissions
3100000
CY2021Q3 us-gaap Cash
Cash
56200000
CY2021Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
300000
CY2020Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these condensed financial statements include, but are not limited to, the fair value of the Company’s common stock, prior to its IPO in connection with share-based compensation arrangements. Actual results could differ from these estimates.</p>
CY2020Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
100000
CY2020Q3 us-gaap Restricted Cash
RestrictedCash
100000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56343000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6844000
imnm Research And Development Milestone Expense
ResearchAndDevelopmentMilestoneExpense
0
CY2020Q3 imnm Research And Development Milestone Expense
ResearchAndDevelopmentMilestoneExpense
0
imnm Research And Development Milestone Expense
ResearchAndDevelopmentMilestoneExpense
0
CY2021Q3 imnm Research And Development Milestone Expense
ResearchAndDevelopmentMilestoneExpense
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3250769
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8021647
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q3 us-gaap Payments For Rent
PaymentsForRent
100000
us-gaap Payments For Rent
PaymentsForRent
200000
CY2021Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
14115
CY2020Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
41700000
CY2020Q4 imnm Payments Of Underwriting Discounts And Commissions
PaymentsOfUnderwritingDiscountsAndCommissions
3100000
CY2021Q3 imnm Deferred Research Obligations Liabilities Current
DeferredResearchObligationsLiabilitiesCurrent
141000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1107000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
845000
CY2021Q3 imnm Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
2524000
CY2020Q4 imnm Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
9000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
606000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
417000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
94000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
101000
CY2021Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
4472000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1372000
us-gaap Payments For Rent
PaymentsForRent
200000
CY2021Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
33000
CY2020Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
18000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
50000
CY2021Q3 imnm Collaborative Arrangements License Fee Payable On Certain Development Regulatory And Commercial Milestones For Each Product
CollaborativeArrangementsLicenseFeePayableOnCertainDevelopmentRegulatoryAndCommercialMilestonesForEachProduct
2600000
imnm Common Stock Voting Right
CommonStockVotingRight
1
CY2021Q3 us-gaap Payments For Rent
PaymentsForRent
100000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
1300000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1155000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
117000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2229000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
302000
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
13500000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y4M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.831
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.822
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.010
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.006
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y14D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3D
CY2021Q3 imnm Fair Value Of Common Stock
FairValueOfCommonStock
23.61
CY2020Q3 imnm Fair Value Of Common Stock
FairValueOfCommonStock
1.95
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
8.69

Files In Submission

Name View Source Status
0001558370-21-015969-index-headers.html Edgar Link pending
0001558370-21-015969-index.html Edgar Link pending
0001558370-21-015969.txt Edgar Link pending
0001558370-21-015969-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20210930.xsd Edgar Link pending
tmb-20210930x10q.htm Edgar Link pending
tmb-20210930x10q_htm.xml Edgar Link completed
tmb-20210930xex10d2.htm Edgar Link pending
tmb-20210930xex31d1.htm Edgar Link pending
tmb-20210930xex31d2.htm Edgar Link pending
tmb-20210930xex32d1.htm Edgar Link pending
tmb-20210930xex32d2.htm Edgar Link pending
tmb-20210930_cal.xml Edgar Link unprocessable
tmb-20210930_def.xml Edgar Link unprocessable
tmb-20210930_lab.xml Edgar Link unprocessable
tmb-20210930_pre.xml Edgar Link unprocessable